Kyverna is Developing Cell Therapies for Autoimmune Diseases
Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing CAR T-cell therapies designed to achieve treatment-free remission in autoimmune diseases. Its lead candidate, mivocabtagene autoleucel (KYV-101), is in Phase 2 trials across lupus nephritis, multiple sclerosis, myasthenia gravis, and stiff-person syndrome. Kyverna went public on Nasdaq in February 2024.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNov 2025
Feb 2024
Aug 2023
Jan 2020
Create a free account to see which investors have funded this company.
Create Free Account
Health insurance company using technology to make health care simple, affordable, and accessible.
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage biotechnology company developing PROTAC protein degraders for oncology and neurode...
Alumis is a late-stage biopharma company developing targeted therapies for patient with immune-me...
